Treatment
Share your love
Dr. Mali’s top 5 predictions in ophthalmology for 2026 | Ophthalmology Times
From artificial intelligence to retinal care and postoperative protection, Joshua Mali, MD, FASRS, offers five predictions shaping ophthalmology in 2026. (Image credit: AdobeStock/Sam Efendi) It’s that exciting time of the year again when I reveal my top 5 predictions in…
Moorfields study reveals sharp rise in glaucoma burden across the UK | Ophthalmology Times
(Image Credit: AdobeStock/Vitalii) A recent press release issued by Moorfields Eye Hospital announced startling glaucoma prevalence data based on a new study1 published in the British Journal of Ophthalmology. The data estimate that the prevalence of glaucoma currently is almost…
Nanoscope’s gene therapy, MCO-010 receives Sakigake and Orphan Drug Designations in Japan | Ophthalmology Times
(Image Credit: AdobeStock/sezerozger) Nanoscope Therapeutics has received Pioneering Regenerative Medical Product (Sakigake) and Orphan Drug designations for MCO-010 from Japan’s Ministry of Health, Labour and Welfare (MHLW), making it the first retinal gene therapy to do so in Japan. Sakigake designation is Japan’s…
Q&A: Evolving approaches to geographic atrophy management | Ophthalmology Times
(Image Credit: AdobeStock/Prostock-studio) Management of geographic atrophy (GA) has changed with the introduction of retinal therapies aimed at slowing disease progression and with greater use of imaging for diagnosis and monitoring. These developments have raised practical questions about patient selection,…
Q&A: Understanding Medicare payment shifts in eye care | Ophthalmology Times
Dustin D. French, PhD, examines 2 decades of Medicare reimbursement trends in ophthalmology, highlighting how changes in conversion factors, relative value units, and practice settings are affecting subspecialties and practice sustainability. (Image credit: AdobeStock/thatinchan) Medicare reimbursement for ophthalmology procedures has…
PRIMA retinal implant restores vision in patients with advanced GA | Ophthalmology Times
(Image Credit: AdobeStock/stockbusters) An editorial published in the New England Journal of Medicine1 referred to the Photovoltaic Retina Implant Microarray (PRIMA) Implant (Science Corporation) as “the first treatment to restore vision” in patients with advanced geographic atrophy (GA) associated with…
Ocugen releases positive preliminary 12-month data from phase 2 ArMaDa trial | Ophthalmology Times
(Image Credit: AdobeStock/LORA) Ocugen has announced positive preliminary 12-month data from its phase 2 ArMaDa trial evaluating OCU410 (AAV5-RORA) for the treatment of geographic atrophy secondary to dry age-related macular degeneration. OCU410 is an investigational, intravitreally administered, AAV5-based gene therapy…
Ophthalmology pipeline watch: Key trial results and PDUFA dates for Q1 2026 | Ophthalmology Times
(Image Credit: AdobeStock/Iuliia Pilipeichenko) Editor’s Note: This content was generated with the assistance of AI. Clinical trial watchers can anticipate the release of data from a number of trials in the first quarter of 2026. The trials focus on Leber hereditary…
FDA grants Fast Track Designation to Complement Therapeutics’ CTx001 for geographic atrophy | Ophthalmology Times
(Image Credit: AdobeStock/Tada Images) The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the company’s lead gene therapy candidate for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The…
Moorfields launches world’s first dedicated hypotony clinic | Ophthalmology Times
(Image courtesy Moorfields Eye Hospital) The world’s first dedicated hypotony clinic, funded by Moorfields Eye Charity, has been established at the Moorfields Eye Hospital, London, according to a press release. Physicians there reported that treatment of hypotony with hydroxypropyl methylcellulose…